X
ACHEMA MIDDLE EAST
Pharma Advancement
DDF Summit
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Drug Manufacturing

    GSK to Invest $30B in Drug Manufacturing and R&D in the US

    Sodium Oxybate Oral Solution

    Amneal Secures FDA Approval for Sodium Oxybate Oral Solution

    Bladder Cancer Treatment

    US FDA Approves Bladder Cancer Treatment Inlexzo from J&J

    Lilly TuneLab

    Eli Lilly Unveils Lilly TuneLab for AI-driven Drug Discovery

    Sensor Technology

    Enhancing Clinical Research with Advanced Sensor Technology

    Recombinant VWF

    FDA Approves Recombinant VWF Treatment in Pediatric Patients

    Novartis and Argo

    Novartis and Argo Signs Deal of up to $5.2b for Heart Drugs

    Novartis and Arrowhead

    Novartis and Arrowhead Sign Deal to Advance Parkinson’s Drug

    Eisais Leqembi IQLIK

    FDA Approves Eisai’s Leqembi IQLIK for Alzheimer’s Treatment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Drug Manufacturing

    GSK to Invest $30B in Drug Manufacturing and R&D in the US

    Sodium Oxybate Oral Solution

    Amneal Secures FDA Approval for Sodium Oxybate Oral Solution

    Bladder Cancer Treatment

    US FDA Approves Bladder Cancer Treatment Inlexzo from J&J

    Lilly TuneLab

    Eli Lilly Unveils Lilly TuneLab for AI-driven Drug Discovery

    Sensor Technology

    Enhancing Clinical Research with Advanced Sensor Technology

    Recombinant VWF

    FDA Approves Recombinant VWF Treatment in Pediatric Patients

    Novartis and Argo

    Novartis and Argo Signs Deal of up to $5.2b for Heart Drugs

    Novartis and Arrowhead

    Novartis and Arrowhead Sign Deal to Advance Parkinson’s Drug

    Eisais Leqembi IQLIK

    FDA Approves Eisai’s Leqembi IQLIK for Alzheimer’s Treatment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

In US, FedEx faces drug trafficking charges

Yuvraj_pawp by Yuvraj_pawp
31st July 2014
in Americas, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The courier firm FedEx faces drug-trafficking charges after being indicted by a federal grand jury in California, in a case that highlights the growth in illegal online pharmacies selling dubious medication to people without prescription.

The 15-count indictment accuses FedEx of conspiring in the delivery of illicit pharmaceuticals, including the sleep aid Ambien and the slimming drug phendimetrazine, despite repeated warnings from the authorities.

During the period covered by the indictment, between 2000 and 2010, FedEx is alleged to have adopted special policies governing the dubious deliveries that would prevent its employees being penalized if a pharmacy closed for business. Prosecutors said the firm made some $820m (£480m) by turning a blind eye to the questionable trade.

US attorney Melinda Haag said, “The advent of internet pharmacies allowed cheap and easy distribution of illegal prescription drugs to every part of the US, while allowing perpetrators to conceal their identities… This indictment highlights the importance of holding corporations that knowingly enable illegal activity responsible for their role in aiding criminal behaviour.” Marjorie Clifton, the executive director of the not-forprofit Center for Safe Internet Pharmacies, said over 100,000 deaths a year are linked to prescription drugs that have been bought online.

Tags: AmericaFedEx faces drug trafficking charges
Previous Post

Eisai and Arena Pharmaceuticals Announce BELVIQ(R) (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category

Next Post

Meda agrees to acquire Rottapharm for €2.3bn

Related Posts

Drug Manufacturing
Americas

GSK to Invest $30B in Drug Manufacturing and R&D in the US

18th September 2025
Sodium Oxybate Oral Solution
Drug Development

Amneal Secures FDA Approval for Sodium Oxybate Oral Solution

17th September 2025
misleading drug advertising
Facilities & Operation

US FDA Tightens Oversight on Misleading Drug Advertising

16th September 2025
Bladder Cancer Treatment
Drug Development

US FDA Approves Bladder Cancer Treatment Inlexzo from J&J

13th September 2025
Lilly TuneLab
Drug Development

Eli Lilly Unveils Lilly TuneLab for AI-driven Drug Discovery

12th September 2025
Recombinant VWF
Drug Development

FDA Approves Recombinant VWF Treatment in Pediatric Patients

9th September 2025
Next Post

Pfizer to acquire Baxter’s portfolio of marketed vaccines for $635m

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In